Long-Term Routine Laboratory Toxicity Monitoring of Immunomodulatory Drugs in Rheumatoid Arthritis
Year: 2025
Type: article
Study design: Observational Study
Abstract: BACKGROUND: Scarcity of data on the value of long-term routine laboratory toxicity monitoring (lt-RLTM) during disease-modifying antirheumatic drug (DMARD) use results in frequent monitoring in clinical practice. OBJECTIVE: To determine the cumulative incidence of abnormal and very abnormal laboratory monitoring results among patients with rheumatoid arthritis (RA) and to characterize the clinical context for the incidence of new very abnormal results. DESIGN: Retrospective cohort study. SETTING: The Netherlands, July 2008 to April 2020. PATIENTS: Patients with RA undergoing lt-RLTM after at least 6 months of DMARD use. MEASUREMENTS: /L). Chart review for newly occurring very abnormal results was performed for clinical context. RESULTS: and 61% for Hb level below 7.5 mmol/L for females or below 8 mmol/L for males. LIMITATION: The possibility that regular monitoring contributed to lack of serious adverse outcomes cannot be excluded. CONCLUSION: Routine laboratory monitoring after 6 months of DMARD use revealed that most very abnormal laboratory results were already clinically anticipated and often occurred after dose escalation, although the cumulative incidence of some less serious abnormal results was quite high. Strategies for lt-RLTM warrant reconsideration. PRIMARY FUNDING SOURCE: None.
Source: Annals of Internal Medicine
Language: English
Subfield: Rheumatology
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W4413514393